59 citations,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
Ayurvedic herbs may reduce side effects and improve effectiveness of cancer treatments.
May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
68 citations,
January 2022 in “International Journal of Molecular Sciences” PCOS management includes lifestyle changes and medications, with ongoing research into repurposed drugs for better treatment options.